BioSpace News Archive

Drug Development

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

Medivir AB announced that the 15th patient with advanced hepatocellular carcinoma has been included in the ongoing phase 2a study.

August 14, 2023
·
4 min read
BioMidwest

DurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Anteris Technologies Ltd reported that DurAVR™ THV, a new class of biomimetic heart valve and the world’s only balloon-expandable, single-piece transcatheter aortic valve was implanted in a second successful Valve-in-Valve procedure as part of Health Canada’s Special Access Program.

August 14, 2023
·
5 min read
Lone Star Bio

The Caris Precision Oncology Alliance Welcomes NRG Oncology

Caris Life Sciences® announced that NRG Oncology, a National Cancer Institute National Clinical Trials Network cooperative group, has joined the Caris Precision Oncology Alliance™.

August 14, 2023
·
5 min read
Business

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its second quarter 2023 financial results and provided a corporate update.

August 14, 2023
·
9 min read
Business

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today reported financial results and business highlights for the second quarter ended June 30, 2023.

August 14, 2023
·
13 min read
Business

HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

HilleVax, Inc. reported financial results for the quarter ended June 30, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis.

August 14, 2023
·
6 min read
Business

Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update

Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2023, and provided an update on the business.

August 14, 2023
·
15 min read
Business

BIO-TECHNE ENDS COLLABORATION PROGRAM WITH AKOYA TO AUTOMATE RNASCOPE ON THE PHENOCYCLER FUSION

Bio-Techne today announced that the company will end their collaboration with Akoya Biosciences to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System.

August 14, 2023
·
1 min read
Business

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Leap Therapeutics, Inc. today reported financial results for second quarter ended June 30, 2023.

August 14, 2023
·
11 min read
Deals

HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc.

August 14, 2023
·
13 min read